





6^e JNI


Génétique et Sepsis

9 Juin 2005

Jean-Paul Mira





Réanimation Médicale & Dept. de Biologie Cellulaire
Hôpital Cochin & Institut Cochin, Paris, F






« If it were not for the great variability among individuals medicine might as well be a science and not an art »


Sir William Osler, 1892



-1953-

2001-2003 →





« Today we are learning the language in which God created life. It will revolutionize the diagnosis, prevention and treatment of most, if not all human diseases. »

William J. Clinton, June 26, 2000

From Watson and Crick to Human Genome

- 1953 Watson and Crick: double helical structure of DNA
- 1960s Role of RNA and Genetic Code
- 1970s Recombinant DNA technology
- 1977 Sanger and Gilbert: DNA sequencing
- 1983 Mapping of disorders by linkage (Huntington disease)
- 1986 Polymerase Chain Reaction
- 1990 Human Genome Project
- 1995 *Haemophilus influenzae* genome
- 2003 Mice and Human genome sequence
Human SNP Map






Genetic Polymorphisms



→ Human SNP Map

How single nucleotide polymorphisms influence human biology



Evidences for a genetic component to sepsis

Animal Studies


- Susceptibility/resistance to certain infection in mice
- Susceptibility/resistance phenotypes of knockout mice

Human Studies

- Clinical Evidences
- Ethnic Differences
- Twin Studies
- Adoptee Studies



Pneumococcal Bacteremia by Ethnic and Age





Monroe County, New York, 1985-1989

Bennet NM; Am J Public Health 1992;82:1513


Genetic Polymorphisms and Severe Sepsis

Gene	Susceptibility and/or Outcome
Mannose Binding Lectin	Meningococemia, Pneumococemia Severe sepsis
Toll-Like Receptor 4/2	Gram negative/positive Septic Shock
Toll-Like Receptor 5	Legionnaire's Disease
CD14	Septic Shock
FCgRII Receptor	Meningococemia; Pneumococemia
TNF locus	Meningococemia Septic Shock; Cerebral Malaria
IL-18	Severe Sepsis
IL-10	Severe Sepsis, Meningococemia
IL-6	Severe sepsis
IL-1 locus	Severe Sepsis
IL-4	Viral Pneumonia
Caspase 12	Severe Sepsis
PAI-1	Meningococemia; Severe sepsis
Factor V Leiden	Meningococemia; Severe sepsis

Pathogen Detection




TLR2 and *Streptococcus pneumoniae* meningitis




Echchannaoui H et al. JID 2002;186:798

Mannose-Binding Lectin




- Collectin
- Structural homology with C1q
- Associated to 2 serine proteases
- Variability:
 - Point mutations codons 52, 54, 57
 - Polymorphisms in the promoter




Mannose-binding Lectin Polymorphisms & The Risk of Infections

- Repeated bacterial and fungal infections
 - Sumiya et al., Lancet 1991
 - Summerfeld et al., Lancet 1995
 - Garred et al., Lancet 1995
 - Summerfeld et al., BMJ 1997
- Infections after chemotherapy
 - Neth et al., Lancet 2001
 - Peterslund et al., Lancet 2001
- Increased severity of lung disease and low survival in cystic fibrosis
 - Garred et al., J. Clin. Invest. 1999
- Meningococcal disease
 - Hibberd et al., Lancet 1999

MBL genotype and risk of invasive pneumococcal disease



Roy et al. Lancet 2002; 359: 1569-1573




Synonymous		Structure	Non-synonymous	
Position	rs number		Position	rs number
35	5743697	<p>Extracellular</p> <p>Intracellular</p>	411 (T/I)	5743699
199	3804099		556 (I/T)	5743702
213	5743698		579 (R/H)	5743703
450	3804100			
541	5743700			
542	5743701			
707	IIPGA-TLR2-31410		631 (P/H)	5743704
			677 (R/W)	5743706
			715 (Y/N)	5743707
			753 (R/Q)	5743708
781	5743709			

Increased susceptibility to

- *Mycobacterium tuberculosis*
Cytokine 2002;20(2):56-62
- *Mycobacterium leprae*
J Immunol 2003;170(7):3451-4

R753Q Polymorphism in the TLR2 gene




Lorenz, Infect. Immun. 2000

TLR2_{R753Q} in MICU



1103 Caucasian ICU Pts (322 SS) → 28 Pts TLR2_{R753Q} (2,5%)

- Age 47,2 ± 18
 - SAPS 2 40,5 ± 19
 - Survivors 23/28
 - Infections 16/28 → 16 Septic Shock (5.1% of SS group)
 - Origin of Infections
 - Pneumonia 10
 - Meningitis 4
 - Septicemia 5
 - Others 4
 - Microorganisms
 - S. pneumoniae 8
 - S. aureus 5
 - Candida sp. 2
 - Aspergillus sp. 2
 - Others 6
- 11.1% of Gram positive SS group



Cytokine Polymorphisms and Meningococemia


Gene	Polymorphism	Csqqs	Pts	Su	Severity	Outcome	Ref
ACE	DD (deletion)	- ACE	110			↑14% Death [OR]= 2.8	Harding D. 2002
TNF	- 308 (TNF2)	- TNF a	98			[OR] =2.5 [CI]: 1.1-5.7	Nadel S. 1996
IL-6	-174 (G→C)	- IL-6	85		[OR]= 3.06	[OR] = 2.64 [CI]: 1.1- 6.2	Balding J. 2001
IL-1B ILRN	-511 (1+) +2018 (2+)	→ IL-1b - IL -1b	1106			[OR] = 0.61 [CI] 0.38-0.98	Read RC. 2003



Severity of Community-acquired Pneumonia, LTa & HSP70-2 Polymorphisms

343 Community-acquired pneumonias ; 30 SS

No link with mortality



HSP70-2 +1267AA: OR = 3.5 (1.8–6.8); LTa+250 AA genotype OR= 2.7 (1.4 – 5.3)

Waterer GW. Crit Care Med 2003; 31: 1367

Perspectives and Conclusions

- ⇒ Screening of a high number of polymorphisms in large cohorts
 - ⇒ SNPs or haplotype
 - ⇒ Micro-arrays, Taqman, Mass Spectroscopy, ...

Yamada Y et al. *N Engl J Med* 2002; 347: 1916-23.

⇒ 2819 patients with myocardial infarction

⇒ 2242 controls

⇒ 112 polymorphisms of 71 candidate genes

PAI-1, connexin 37, stromelysin


Perspectives et Conclusions

- Screening of a high number of polymorphisms in large cohorts
 - ⇒ UK: 1000 Patients – Peritonitis
 - ⇒ UK: 2000 Patients – Community-Acquired Pneumonia
 - ⇒ USA: 2000 Patients – Severe Sepsis
 - ⇒ USA: 1500 Patients – Severe Sepsis
 - ⇒ France: 3500 Patients – Nosocomial Pneumonia
 - ⇒ France: 3500 Severe Trauma
 - ⇒ Australia ?
 - ⇒ Japan ?

High Throughput Genotyping




20'



30'



90'



Recurrent Purpura Fulminans

2002/01: 15 yo girl admitted in ICU

- Temperature 40°C; HR 125; BP 74/45; RR 38
- Meningitis with purpura fulminans
- MOF (Shock, ARDS, ARF, DIC, Lactic acidosis)
- Meningococcus type N in the skin biopsy
- Survival with multiple finger amputations and skin grafting
- 6 month hospitalization

2003/02:

- Temperature 39°C; HR 125; BP 83/48; RR: 33
- Meningitis with purpura fulminans
- Lumbar puncture → meningococcus type Y
- Shock and DIC
- Survival (Xigris) with new skin grafting
- 3 month hospitalization

Bohé J. Clin Infect Dis 2005

Recurrent Purpura Fulminans

Genetic predisposition?

Innate immunity

Inflammation

Coagulation

Innate Immunity

TLR4

CD14

FcγRIIa

FcγRIII

MBL

Complement

C7 deficiency

Inflammation

TNFα

LTα

IL-1

IL-6

IL-10

ACE

Coagulation

Tissue Factor

Prothrombin


Factor V

Factor VII

Factor XIII

PAI-1

Bohé J. Clin Infect Dis 2005



Perspectives and Conclusions

⇒ Screening of a high number of polymorphisms in large cohorts

→ Effect of association of polymorphisms ?

▷ Identify potential markers of susceptibility, severity, and clinical outcome

→ Genetic profiling

→ Individual risk assessment

→ Prevention, Vaccination


→ To tailor prescriptions to each patient

▷ Stratification of patients by genotype in the design of treatment trials

→ Identify potential markers for responders vs non-responders

Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial

ElMor Jirwal, Vemuri M Chirchill, Jean G Ford, Homer A Boushey, Ruben Cherniack, Timothy J Craig, Aaron Deykin, Joanne K Fagan, John Y Fulhy, *Chest* 2004; 126: 1505-12




Interpretation Genotype at the 16th aminoacid residue of the β_2 -adrenergic receptor affects the long-term response to albuterol use. Bronchodilator treatments avoiding albuterol may be appropriate for patients with the Arg/Arg genotype.


Perspectives and Conclusions

- ⇒ Screening of a high number of polymorphisms in large cohorts
 - Effect of association of polymorphisms ?
- ▷ Identify potential markers of susceptibility, severity, and clinical outcome
 - Genetic profiling
 - Individual risk assessment
 - Prevention, Vaccination
 - To tailor prescriptions to each patient
- ▷ Stratification of patients by genotype in the design of treatment trials
 - Identify potential markers for responders vs non-responders
- ▷ SNPs of Pathogen Recognition Receptors leading to Host advantage
 - TLR4 D299G protects from Legionnaire's disease (Hawn TR., PNAS 2005)
 - SNPs from TLR4, CD14, or MBL are associated with low atherosclerosis risk
 - CCR5 and CCL3L1 genotypes and HIV infection


CCL3L1 and CCR5 Phenotypes and HIV Risk



Gonzales E, Science 2005;307:1434



**FUNCTIONAL
GENOMICS OF**



**CRITICAL ILLNESS
AND INJURY**